Cytomorphologic, imaging, molecular findings, and outcome in thyroid follicular lesion of undetermined significance/atypical cell of undetermined significance (AUS/FLUS)

A mini-review

Bita Geramizadeh, Somayeh Bos-Hagh, Zahra Maleki

Research output: Contribution to journalArticle

Abstract

Objectives: Since the introduction of the entity of "Atypical cell of undetermined significance/follicular lesion of undetermined significance" (AUS/FLUS) by The Bethesda System for Reporting Thyroid Cytology (TBSRTC) in 2007, there have been many published studies about the cytomorphologic criteria, subclassification, outcome, and management of patients with the diagnosis of AUS/FLUS. There have been many studies in different aspects of this indeterminate category, i.e., cytologic and molecular findings, ultrasonographic findings, and in some instances even core-needle biopsy to address a better and safer way of the management of patients with this fine-needle aspiration cytology diagnosis. The second edition of TBSRTC and the 2015 American Thyroid Association guidelines provide an update on the follow-up and management of AUS/FLUS. A multidisciplinary team consisting of pathologists, endocrinologists, surgeons, and radiologists should be involved in the diagnosis and management of AUS/FLUS, and all of them should be aware of the heterogeneity of this lesion for the prediction of the treatment and outcome. Study Design: In this review, we consider different research platforms (2008-2017) to find the best and key reports for the above-mentioned challenging aspects of AUS/FLUS. Conclusion: AUS/FLUS is now a well-defined group of thyroid lesions, which can be most accurately diagnosed and managed with cytomorphology, molecular, and ancillary studies.

Original languageEnglish (US)
JournalActa Cytologica
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Molecular Imaging
Thyroid Gland
Cell Biology
Large-Core Needle Biopsy
Fine Needle Biopsy
Guidelines
Research

Keywords

  • Afirma
  • Atypical cell of undetermined significance
  • Fine-needle aspiration
  • Follicular lesion of undetermined significance
  • Molecular and ancillary studies
  • The Bethesda System for Reporting Thyroid Cytology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

@article{fd02975ef23c43afb784213a67ede910,
title = "Cytomorphologic, imaging, molecular findings, and outcome in thyroid follicular lesion of undetermined significance/atypical cell of undetermined significance (AUS/FLUS): A mini-review",
abstract = "Objectives: Since the introduction of the entity of {"}Atypical cell of undetermined significance/follicular lesion of undetermined significance{"} (AUS/FLUS) by The Bethesda System for Reporting Thyroid Cytology (TBSRTC) in 2007, there have been many published studies about the cytomorphologic criteria, subclassification, outcome, and management of patients with the diagnosis of AUS/FLUS. There have been many studies in different aspects of this indeterminate category, i.e., cytologic and molecular findings, ultrasonographic findings, and in some instances even core-needle biopsy to address a better and safer way of the management of patients with this fine-needle aspiration cytology diagnosis. The second edition of TBSRTC and the 2015 American Thyroid Association guidelines provide an update on the follow-up and management of AUS/FLUS. A multidisciplinary team consisting of pathologists, endocrinologists, surgeons, and radiologists should be involved in the diagnosis and management of AUS/FLUS, and all of them should be aware of the heterogeneity of this lesion for the prediction of the treatment and outcome. Study Design: In this review, we consider different research platforms (2008-2017) to find the best and key reports for the above-mentioned challenging aspects of AUS/FLUS. Conclusion: AUS/FLUS is now a well-defined group of thyroid lesions, which can be most accurately diagnosed and managed with cytomorphology, molecular, and ancillary studies.",
keywords = "Afirma, Atypical cell of undetermined significance, Fine-needle aspiration, Follicular lesion of undetermined significance, Molecular and ancillary studies, The Bethesda System for Reporting Thyroid Cytology",
author = "Bita Geramizadeh and Somayeh Bos-Hagh and Zahra Maleki",
year = "2018",
month = "1",
day = "1",
doi = "10.1159/000493908",
language = "English (US)",
journal = "Acta Cytologica",
issn = "0001-5547",
publisher = "Science Printers and Publishers Inc.",

}

TY - JOUR

T1 - Cytomorphologic, imaging, molecular findings, and outcome in thyroid follicular lesion of undetermined significance/atypical cell of undetermined significance (AUS/FLUS)

T2 - A mini-review

AU - Geramizadeh, Bita

AU - Bos-Hagh, Somayeh

AU - Maleki, Zahra

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: Since the introduction of the entity of "Atypical cell of undetermined significance/follicular lesion of undetermined significance" (AUS/FLUS) by The Bethesda System for Reporting Thyroid Cytology (TBSRTC) in 2007, there have been many published studies about the cytomorphologic criteria, subclassification, outcome, and management of patients with the diagnosis of AUS/FLUS. There have been many studies in different aspects of this indeterminate category, i.e., cytologic and molecular findings, ultrasonographic findings, and in some instances even core-needle biopsy to address a better and safer way of the management of patients with this fine-needle aspiration cytology diagnosis. The second edition of TBSRTC and the 2015 American Thyroid Association guidelines provide an update on the follow-up and management of AUS/FLUS. A multidisciplinary team consisting of pathologists, endocrinologists, surgeons, and radiologists should be involved in the diagnosis and management of AUS/FLUS, and all of them should be aware of the heterogeneity of this lesion for the prediction of the treatment and outcome. Study Design: In this review, we consider different research platforms (2008-2017) to find the best and key reports for the above-mentioned challenging aspects of AUS/FLUS. Conclusion: AUS/FLUS is now a well-defined group of thyroid lesions, which can be most accurately diagnosed and managed with cytomorphology, molecular, and ancillary studies.

AB - Objectives: Since the introduction of the entity of "Atypical cell of undetermined significance/follicular lesion of undetermined significance" (AUS/FLUS) by The Bethesda System for Reporting Thyroid Cytology (TBSRTC) in 2007, there have been many published studies about the cytomorphologic criteria, subclassification, outcome, and management of patients with the diagnosis of AUS/FLUS. There have been many studies in different aspects of this indeterminate category, i.e., cytologic and molecular findings, ultrasonographic findings, and in some instances even core-needle biopsy to address a better and safer way of the management of patients with this fine-needle aspiration cytology diagnosis. The second edition of TBSRTC and the 2015 American Thyroid Association guidelines provide an update on the follow-up and management of AUS/FLUS. A multidisciplinary team consisting of pathologists, endocrinologists, surgeons, and radiologists should be involved in the diagnosis and management of AUS/FLUS, and all of them should be aware of the heterogeneity of this lesion for the prediction of the treatment and outcome. Study Design: In this review, we consider different research platforms (2008-2017) to find the best and key reports for the above-mentioned challenging aspects of AUS/FLUS. Conclusion: AUS/FLUS is now a well-defined group of thyroid lesions, which can be most accurately diagnosed and managed with cytomorphology, molecular, and ancillary studies.

KW - Afirma

KW - Atypical cell of undetermined significance

KW - Fine-needle aspiration

KW - Follicular lesion of undetermined significance

KW - Molecular and ancillary studies

KW - The Bethesda System for Reporting Thyroid Cytology

UR - http://www.scopus.com/inward/record.url?scp=85056139486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056139486&partnerID=8YFLogxK

U2 - 10.1159/000493908

DO - 10.1159/000493908

M3 - Article

JO - Acta Cytologica

JF - Acta Cytologica

SN - 0001-5547

ER -